Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 375Neoplasms 325Neoplasm Metastasis 290Leukemia, Myeloid, Acute 282Breast Neoplasms 277Colorectal Neoplasms 239Melanoma 197Ovarian Neoplasms 193Recurrence 187Multiple Myeloma 181Prostatic Neoplasms 157Pancreatic Neoplasms 156Lung Neoplasms 156Squamous Cell Carcinoma of Head and Neck 150Lymphoma, Non-Hodgkin 146Glioblastoma 145Triple Negative Breast Neoplasms 120Myelodysplastic Syndromes 117Carcinoma, Renal Cell 111Stomach Neoplasms 110Glioma 108Advanced Solid Tumors 108Brain Neoplasms 105Precursor Cell Lymphoblastic Leukemia-Lymphoma 104Lymphoma 103Lymphoma, Large B-Cell, Diffuse 102Lymphoma, B-Cell 98Carcinoma, Hepatocellular 95Endometrial Neoplasms 92Lymphoma, Follicular 91

Interventions

trametinib 1ribociclib 1nazartinib 1naporafenib 1capmatinib 1Gefitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × EGFR-mutant Non-small Cell Lung Cancer × 1 year × Clear all
NCT03333343 2026-01-16

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Novartis

Phase 1 Active not recruiting
105 enrolled
Thoracic

EGFR-mutant Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡